Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Unquoted Biotechs -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (2)	8/6/2001 10:01:39 AM
From: nigel bates	Respond to of 253

Schering-Plough and NeoGenesis Announce Research Collaboration To Discover Small-Molecule Drugs KENILWORTH, N.J. and CAMBRIDGE, Mass., Aug. 6 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP - news) and NeoGenesis Drug Discovery, Inc. today announced a multi-year, multi-target research collaboration to discover small-molecule drug candidates. This alliance will draw upon NeoGenesis' innovative drug discovery technologies and Schering-Plough's expertise in experimental biology, pre-clinical research and clinical development of novel drug candidates. The companies entered into this new collaboration based on NeoGenesis' previous success in working with Schering-Plough to identify antiviral drug leads. Under terms of the agreement, Schering-Plough will make an equity investment in NeoGenesis and will provide research and development funding, which may extend over a period of up to five years. NeoGenesis expects to receive license fees as well as payments upon the achievement of certain defined clinical and regulatory milestones. In addition, NeoGenesis will receive royalties on any commercial sales of products resulting from the collaboration. ``We are very pleased to enter into this collaboration with Schering-Plough,'' said Satish Jindal, Ph.D., president and chief scientific officer of NeoGenesis. ``We expect our unique screening technology to yield high-quality leads to a variety of targets provided by Schering-Plough. This partnership further validates NeoGenesis as an industry leader in drug discovery technologies.''...

To: nigel bates who wrote (2)	8/16/2001 10:58:12 AM
From: nigel bates	Respond to of 253

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 15, 2001--NeoGenesis Drug Discovery and Mitsubishi-Tokyo Pharmaceuticals today announced a collaboration agreement to discover small-molecule drug candidates for a high value therapeutic area. This alliance will draw on Mitsubishi-Tokyo Pharmaceutical's experience as a global pharmaceutical company with the chemical genomics-based drug discovery technologies of NeoGenesis, which rapidly translate proteins into small molecule drug leads. ``Our agreement with NeoGenesis demonstrates our desire to contribute to society through the provision of valuable new medicines,'' said Akihiro Tobe, Ph.D., board director, president of Research and Development Division, Mitsubishi-Tokyo Pharmaceuticals. ``Based on their previous record of success, we are confident that in a short period of time, NeoGenesis will be able to provide us with effective drug leads to the target we have supplied them with.'' ``We are excited to be entering into this collaboration with Mitsubishi-Tokyo Pharmaceuticals,'' said Satish Jindal, Ph.D., president and chief scientific officer of NeoGenesis. ``By using our unique screening technology, we will be able to yield high-quality leads to the target supplied to us by Mitsubishi-Tokyo Pharmaceuticals. This partnership further positions NeoGenesis as the industry leader in drug discovery technologies.'' Under terms of the agreement, Mitsubishi-Tokyo Pharmaceuticals will pay NeoGenesis for discovery as well as traditional milestones and royalties on products resulting from the collaboration.